Nymox Pharmaceutical
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Nymox Pharmaceutical generated cash of -$5,205,000, which is more than the previous year. Cash used in financing activities reached the amount of $5,778,000 last year. Net change in cash is therefore $573,000.
Cash Flow
| 2013 | -6.71M | -6.50K | 5.98M |
|---|---|---|---|
| 2014 | -5.51M | -3.52K | 5.85M |
| 2015 | -3.75M | 0 | 3.49M |
| 2016 | -4.50M | -1.78K | 6.14M |
| 2017 | -6.20M | 0 | 5.03M |
| 2018 | -7.80M | -36K | 14.93M |
| 2019 | -7.43M | 0 | 4.72M |
| 2020 | -10.03M | -13K | 8.42M |
| 2021 | -9.82M | -6K | 7.04M |
| 2022 | -5.20M | 0 | 5.77M |
NYMX Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 830K | 3.61M | 5.23M | 7.94M | 851K | 2.01M | 374.46K | 632.27K | 295.52K | 1.03M |
Operating activities | ||||||||||
Net income | -6.57M | -12.53M | -11.73M | -13.16M | -10.59M | -13.42M | -13.10M | -17.89M | -4.59M | -4.90M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 249K | 254K | 267K | 565K | 3K | 1K | 3.43K | 6.00K | 6.64K | 9.10K |
Stock-based compensation expense | 593K | 2.60M | 1.74M | 3.01M | 3.81M | 6.29M | 9.07M | 15.78M | 1.57M | 307.32K |
| Deferred income tax benefit | 593K | 2.60M | 1.74M | 3.01M | 3.81M | 6.29M | 9.07M | 15.78M | 1.57M | 307.32K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 73K | -77K | -1.6K | 52.48K | 160.06K | -135.73K |
Inventories | 0 | 0 | -11K | 17K | -25K | -13K | 35.05K | 50.62K | -48.58K | 2.81K |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | -612.16K | 660.93K | 200.39K | 627.02K |
Cash generated by operating activities | -5.20M | -9.82M | -10.03M | -7.43M | -7.80M | -6.20M | -4.50M | -3.75M | -5.51M | -6.71M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -6K | -13K | 0 | -36K | 0 | -1.78K | 0 | -3.52K | -6.50K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -6K | -13K | 0 | -36K | 0 | -1.78K | 0 | -3.52K | -6.50K |
Financing activities | ||||||||||
Common Stock Issued | 6.00M | 7.28M | 8.68M | 5M | 14.93M | 5.03M | 6.14M | 3.58M | 5.35M | 6.3M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -238K | -265K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 5.77M | 7.04M | 8.42M | 4.72M | 14.93M | 5.03M | 6.14M | 3.49M | 5.85M | 5.98M |
Net Change In Cash | 573K | -2.78M | -1.62M | -2.70M | 7.09M | -1.16M | 1.64M | -257.81K | 336.74K | -734.55K |
Cash at end of period | 1.40M | 830K | 3.61M | 5.23M | 7.94M | 851K | 2.01M | 374.46K | 632.27K | 295.52K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |